Abstract
Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Role of Epigenetics and Oxidative Stress in Gliomagenesis
Volume: 16 Issue: 10
Author(s): Yesennia Sanchez-Perez, Ernesto Soto-Reyes, Claudia M. Garcia-Cuellar, Bernardo Cacho-Diaz, Abel Santamaria and Edgar Rangel-Lopez*
Affiliation:
- National Institute of Neurology and Neurosurgery, Laboratory of Excitatory Amino Acids. Av. Insurgentes Sur #3877 Col. La Fama. Delegacion Tlalpan, C.P. 14269 Mexico City,United States
Keywords: Brain tumors, clinical trials, epigenetics, glioma, malignant, oxidative stress.
Abstract: Background & Objective: Gliomas constitute 81% of malignant brain tumors and exhibit a poor prognosis. Two main events involved in the progression of gliomas are the deregulation of genes via genetic events and the cellular damage resulting from the formation of reactive oxygen species (ROS). In gliomas, epigenetic abnormalities implicated in the deregulation of deoxyribonucleic acid (DNA) methylation, nucleosome rearrangement, and acetylation of histones, have been depicted. The overproduction of ROS has been implicated in the promotion of these modifications.
Conclusion: In this review, we discuss the epigenetic mechanisms and oxidative events that impact gene silencing and its association with the establishment and development of gliomas. Some of these epigenetic marks, or their related proteins, are under investigation for their potential use as biomarkers in clinical trials to propose personalized therapies for patients with glioblastoma.
Export Options
About this article
Cite this article as:
Sanchez-Perez Yesennia, Soto-Reyes Ernesto , Garcia-Cuellar M. Claudia, Cacho-Diaz Bernardo , Santamaria Abel and Rangel-Lopez Edgar *, Role of Epigenetics and Oxidative Stress in Gliomagenesis, CNS & Neurological Disorders - Drug Targets 2017; 16 (10) . https://dx.doi.org/10.2174/1871527317666180110124645
DOI https://dx.doi.org/10.2174/1871527317666180110124645 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Modulating the Hypoxia-Inducible Factor Signaling Pathway: Applications From Cardiovascular Disease to Cancer
Current Pharmaceutical Design The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design 1-Cyclohexylpiperazine and 3,3-Dimethylpiperidine Derivatives as Sigma-1 (σ1) and Sigma-2 (σ2) Receptor Ligands: A Review
Central Nervous System Agents in Medicinal Chemistry Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Exploiting Metabolic Differences in Glioma Therapy
Current Drug Discovery Technologies Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Cellular and Molecular Targeted Drug Delivery: Nanochemistry in Medical Theranostics
Current Topics in Medicinal Chemistry Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Isoflavones, their Glycosides and Glycoconjugates. Synthesis and Biological Activity
Current Organic Chemistry <i>In Vivo</i> Tracking of Novel SPIO-Molday ION Rhodamine-B™-Labeled Human Bone Marrow-Derived Mesenchymal Stem Cells After Lentivirus- Mediated COX-2 Silencing: A Preliminary Study
Current Gene Therapy